ClinicalTrials.gg
DrugBiological

Elotuzumab clinical trials

Also written Empliciti, BMS-901608 and HuLuc63.

studies test it
46
open now
2
in phase 3
6
first study started
2006

How each study uses elotuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the elotuzumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
30 Nov 2015 · EMPLICITI · BLA 761035 (FDA, Drugs@FDA)
European Union
11 May 2016 · Empliciti · EMEA/H/C/003967 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Elotuzumab
38
Elotuzumab (BMS-901608; HuLuc63)
4

Brand

Empliciti
19

Development codes

BMS-901608
15
HuLuc63
14
PDL-063
7

Studies by the year they started

46 studies that test it; most in 2017 (7)

Studies that test elotuzumab, by start year
YearStudies
20061
20082
20115
20123
20131
20142
20154
20166
20177
20185
20192
20213
20221
20231
20242
20251

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
9
Phase 2
33
Phase 3
6

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 18 · Other 28

Bristol-Myers Squibb (12) · M.D. Anderson Cancer Center (3) · Dana-Farber Cancer Institute (3) · Mayo Clinic (2) · University of Arkansas (2) · AbbVie (1) · Yale University (1) · Massachusetts General Hospital (1)

Often tested with

Tested in the same studies.

Dexamethasone (15) · Lenalidomide (8) · Pomalidomide (7) · Carfilzomib (4) · Bortezomib (4) · Iberdomide (3) · Daratumumab (2) · Nivolumab (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 5 phase 3 studies under way

Elotuzumab is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 3

Studies that test elotuzumab.

Studies

Open first, then newest update. How each study uses elotuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 46

See all 46 studies that test elotuzumab →

Given beside what is tested · 10 — elotuzumab is usual care or a partner of the new treatment
As the comparator · 7 — what is tested is compared with elotuzumab

Codes

What other systems call elotuzumab · ClinicalTrials.gg INT005550

  • MeSH (NLM) C546027elotuzumabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 1351PE5UGSELOTUZUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 1726104Confirmed FDA, Wikidata
  • Wikidata Q3723645elotuzumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C66982ElotuzumabOne source FDA
  • DrugBank DB06317One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.